-
Portola's AndexXa Still Approvable, But It Will Take Time
Friday, August 19, 2016 - 11:45am | 405Morgan Stanley’s Matthew Harrison believes regulatory updates regarding AndexXa and betrixaban were key drivers for Portola Pharmaceuticals Inc (NASDAQ: PTLA), which could offer clarity regarding approval timelines and restore investor confidence. Harrison maintains an Overweight rating on...